https://t.co/CeBube0AhQ Long awaited ms @CR_AACR on pri/mets #PDAC! Many year effort @WinshipAtEmory led by #emilygreene and @natalie_horvat with collabs @cameron_herting @Egrunds @AyanaTRuffin @skmaithel @MihirMShah1 @MariaDiab101 @olatunji @HaydnKissick @Chrystal_Paulos +more

Desde @GrupoGetne os deseamos una Feliz Navidad y esperamos que el próximo 2026 se cumplan todos vuestros propósitos. Seguiremos trabajando para que los pacientes tengan nuevas opciones de tratamiento y la máxima calidad de vida. Un abrazo muy fuerte‼️

Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable #PDAC 🔎PACT-21 CASSANDRA) phs 3 @TheLancet https://t.co/RHB2UBFo6G 🧐PAXG significantly improved EFS compared with mFOLFIRINOX in resectable or borderline resectable PDAC @myESMO

CASSANDRA trial (@TheLancet ): Preoperative PAXG (gemcitabine, nab-paclitaxel, capecitabine, cisplatin) beats mFOLFIRINOX in resectable/borderline PDAC. • Median EFS: 16 vs 10.2 mo (HR 0.63, p=0.0018) • more neutropenia, but less neutopathy • But significant number of EFS

Mesoappendix invasion not a criteria for right hemi in appendix #NETs🦓 👥4800 pts 🔬meso invasion not associated with LN+ on its own 📏size main risk factor No difference in OS appendectomy vs right hemi👌 Timely for new @NANETS1 guidelines! 🔗📝 https://t.co/2tK4DSs49n

TTD Young Researchers @GrupoTTD Que buen equipo 🧑‍🧑‍🧒‍🧒🤩

Thrilled to see our correspondence published in JCO! We highlight that LAPC requires individualized restaging to unlock the true surgical conversion potential of FOLFIRINOX. Congrats to the whole team! 🔬👏 @Orhunakdogan91 @DrOzanYazc1 @tubaugurdr https://t.co/C0LkPNLMDU

Check out this excellent summary of the recently published SEQTOR trial in advanced panc NETs by @sonbol_bassam Everything you need to know is there...

8/8 Bottom line: although STZ/5-FU did not beat everolimus, the study confirms what we do in practice that for higher grade and when response is needed, chemo is the way to go. Everolimus remains a valid option, but PRRT has clearly moved up the line based on COMPETE. COMPOSE

1/8 🚨 SEQTOR phase 3 just published in @esmoopen (@GrupoGETNE) Everolimus vs Streptozotocin/5-FU (STZ/5-FU) as 1st-line in advanced pancreatic NETs Spoiler: STZ/5-FU is NOT superior to everolimus Let’s break it down 👇 #NETs #Oncology

💬 "Es interesante dar visibilidad a los tumores raros para que los pacientes podamos conseguir mejores tratamientos" 🎥 En la última #VHIOTalks25 profesionales y pacientes compartieron dudas y experiencias sobre tumores neuroendocrinos. #SOMMVHIO @SOMM_alliance @FCLP_Fundacio

Young Voices in Global Oncology🌍 We’re excited to spotlight early-career oncologists, Dr @ErulEnes (Turkey)and Dr Imène Hadji (Algeria) sharing their journeys, challenges, and innovations in diverse healthcare settings. Stay tuned🚀! @Ioanna_Nixon @DrVilmaPBarcia @OncoAlert

🚨Exploring the Carcinoid Crisis:insights from a Cáncer specific centre. A study carried out at @PeterMacCC thanks to @ENETS_ORG . Discovery fresh insights that could reshape understanding of CC. 👇READ FULL ARTICLE 🚨 https://t.co/pYABQyXwg9

Enhorabuena a @Ja_Capdevila, @RamonSalazarS y todo el equipo del estudio #SEQTOR por la publicación en @ESMO_Open. 🦓 Uno de los estudios más importantes de @GrupoGetne, que ayuda a optimizar la secuencia terapéutica en pacientes con TNE pancreático. 👨🏻‍⚕️ https://t.co/i0n3EQdUka

Moffit´s study (Nature genetics 2015) Identified for the first time 2 tumors and stromal expression programs with independent prognostic value BASAL-like = worse OS ACTIVATED stroma = poor prognosis Combined 4 groups How do we bring it to clinic and tailor treatment?

🧬 SEQTOR phase III (panNETs) 🟦 Everolimus vs STZ/5-FU as sequence therapy 📊 12-m PFS1: 71.4% vs 61.8% 🎯 ORR: higher with STZ/5-FU (1L 30% vs 12%) ⏳ OS: no significant difference 🧩 Both valid options — sequencing must be individualized 💙 Great news for @GrupoGetne 🔗

🔊🔊 SEQTOR trial finally published!!! Amazing international effort led by @RamonSalazarS and our great @GrupoGetne 🙌🏼🦾 @VHIO @vallhebron @ICO_oncologia Streptozotocin plus 5-fluorouracil followed by everolimus or the rever...

💙 Avui entrem a quiròfan per mostrar-vos una intervenció d’alta complexitat en un pacient amb un càncer de pàncrees localment avançat. Fa uns dies us vam presentar el cas i avui en veureu el desenvolupament: des de la laparoscòpia inicial per descartar malaltia metastàtica fins

7% of neuroendocrine tumors (including 45% of duodenal NETs & 13% of pancreatic NETs) express GLP-1R, per @PoHienEar & @IHC_guy: Variable GLP-1 receptor expression across diverse neuroendocrine neoplasms: implications for incretin therapies https://t.co/vbxct7eTqR

✨Thank you @Nutricia for the opportunity to present our work from Spain at the Oncology Expert Day 2025 and to my colleagues for the amazing team work on the consensus on #nutritional management in upper GI malignancies.Grateful for the shared commitment to advancing our field.